Sage and Biogen Report Results of Zuranolone in P-III (CORAL) Study for the Treatment of Major Depressive Disorder
Shots:
- The P-III (CORAL Study/217-MDD-305) evaluates the efficacy & safety of zuranolone (50mg) co-initiated with an SoC ADT vs SoC ADT + PBO in 440 adults with MDD
- The trial met its 1EPs & 2EPs i.e., reduction in depressive symptoms @3 Day & ~2wks., reduction in HAMD-17 score @ Days 8 & 12 while Day 15 showed numerical superiority & Day 42 showed equivalence, 180 (84.9%) received zuranolone + ADT & 177 (81.2%) received ADT + PBO, was well-tolerated with no new safety signals
- Additionally, no evidence of increased suicidal ideation/behavior, TEAEs leads to discontinuation (6.6% vs 3.7%). The company plans to start the rolling submission for NDA in MDD in 2022 with expected completion in H2’22
Ref: Biogen | Image:Biogen
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com